Ensysce Biosciences Files Proxy Materials

TL;DR

Ensysce Biosciences filed proxy docs, no new fee. All good.

AI Summary

Ensysce Biosciences, Inc. filed a Definitive Additional Materials (DEFA14A) on November 19, 2024. This filing relates to the company's proxy statement and does not require a new filing fee. The company is located at 7946 Ivanhoe Avenue, Suite 201, La Jolla, California.

Why It Matters

This filing indicates that Ensysce Biosciences is proceeding with corporate actions requiring shareholder approval or information, as detailed in their proxy statement.

Risk Assessment

Risk Level: low — This is a routine filing of additional proxy materials and does not inherently represent new risks.

Key Players & Entities

• Ensysce Biosciences, Inc. (company) — Registrant
• 0001493152-24-046758 (filing_id) — Accession Number
• 20241119 (date) — Filing Date
• 7946 Ivanhoe Avenue, Suite 201, La Jolla, California 92037 (address) — Company Business and Mail Address
• Leisure Acquisition Corp. (company) — Former Company Name

FAQ

Filing Documents

• formdefa14a.htm (DEFA14A) — 30KB
• formdefa14a_001.jpg (GRAPHIC) — 4KB
• formdefa14a_002.jpg (GRAPHIC) — 6KB
• 0001493152-24-046758.txt ( ) — 44KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to §240.14a-12 Ensysce Biosciences, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. 7946 Ivanhoe Avenue, Suite 201, La Jolla, California 92037 SUPPLEMENT TO THE PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held On November 21, 2024 This proxy statement supplement, dated November 19, 2024 (this “Supplement”), amends and supplements the definitive proxy statement on Schedule 14A filed by Ensysce Biosciences, Inc. (the “Company” or “Ensysce”) with the Securities and Exchange Commission (the “Commission”) on October 18, 2024 (the “Proxy Statement”) and made available to the Company’s stockholders in connection with the solicitation of proxies for the Company’s 2024 Annual Meeting of Stockholders (the “Annual Meeting”) to be held on Thursday, November 21, 2024, at 9:00 a.m., Pacific Time. This Supplement is being filed with Commission and made available to stockholders on or about November 19, 2024. This Supplement does not change the proposals to be acted on at the Annual Meeting or the recommendations of the Board of Directors of the Company in the Proxy Statement. The New York Stock Exchange (the “NYSE”) notified us on November 19, 2024 that Proposal 2 (Reverse Stock Split), Proposal 4 (ratification of independent accounting firm) and Proposal 5 (Additional Solicitation Proposal) in the Proxy Statement are discretionary or “routine” matters under NYSE rules. The “routine” designation permits brokerage firms, banks, dealers, custodians or other similar organizations acting as nominee (each, a “Broker”) to exercise discretionary voting authority on those proposals. Accordingly, if you do not instruct your Broker on how to vote your shares on Proposals 2, 4 and 5, your Broker will be permitted to vote your shares in its discretion on those three proposals. Due to the NYSE’s determination, we do not expect “broker non-votes” in connection with those three proposals. The Proxy Statement states that there is discretionary voting authority on Proposal 4 but does not state that there is discretionary voting authority on Proposals 2 and 5. The sole purpose of this Supplement is to clarify and correct in two places in the Proxy Statement that Proposal 2 and the Additional Solicitation Proposal are considered “routine matters,” and, therefore, brokers have discretionary authority to vote on such Proposals. The Company hereby revises one sentence on page 2 in Question and Answer 7 under the caption, “ Questions and Answers about the Annual Meeting and Voting ” in the Proxy Statement (change underlined): 7. You may vote “FOR,” “AGAINST” or “ABSTAIN” on each of the proposals. If you submit your proxy but abstain from voting on one or more matters, your shares will be counted as present at the meeting for the purpose of determining if a quorum exists. If you abstain from voting on a proposal, your abstention will have no effect on that proposal. If your shares are registered in your name or if you have stock certificates, they will not be counted if you do not vote as described above under “— 5. How do I cast my vote? ” If your shares are held in street name and you do not provide voting instructions to your financial institution as described above, your financial institution does not have the discretionary authority to vote your shares regarding Proposal 1 or Proposal 3 . Therefore, we encourage you to provide voting instructions to your financial institution. This ensures your shares will be voted at the Annual Meeting and in the manner you desire. A “Broker Non-Vote” will occur if your financial institution does not receive instructions from you. In addition, the Company hereby revises the chart on page 34 under “ VOTING AND PROXY PROCEDURES--Votes Required for Each Proposal ” (change underlined): Votes Required for Each Proposal To approve the proposals being considered at the Annual Meeting, the voting requirements are as follows: Proposal Vote Required Discretionar

View Full Filing

View this DEFA14A filing on SEC EDGAR